Abeona Therapeutics

Abeona Therapeutics

Biotechnology, 1330 Ave of the Americas Fl 33, New York, 10019, United States, 51-200 Employees

abeonatherapeutics.com

  • facebook
  • twitter
  • LinkedIn

phone no Phone Number: 21********

Who is ABEONA THERAPEUTICS

Abeona Therapeutics (Nasdaq: ABEO) is a fully-integrated gene and cell therapy company at the forefront of the rapidly-advancing field of genetic medicine. The Companys multi-platform exp...

Read More

map

industries-icon Industry: Biotechnology

SIC SIC Code: 2834 | NAICS Code: 325412 | Show More

checked-icon Does something look wrong? Fix it. | View contact records from ABEONA THERAPEUTICS

signout-image
You are signed out

Sign in to CIENCE GO Data to uncover contact details

crown-icon Free credits every month

Frequently Asked Questions Regarding Abeona Therapeutics

Answer: Abeona Therapeutics's headquarters are located at 1330 Ave of the Americas Fl 33, New York, 10019, United States

Answer: Abeona Therapeutics's phone number is 21********

Answer: Abeona Therapeutics's official website is https://abeonatherapeutics.com

Answer: Abeona Therapeutics's revenue is $25 Million to $50 Million

Answer: Abeona Therapeutics's SIC: 2834

Answer: Abeona Therapeutics's NAICS: 325412

Answer: Abeona Therapeutics has 51-200 employees

Answer: Abeona Therapeutics is in Biotechnology

Answer: Abeona Therapeutics contact info: Phone number: 21******** Website: https://abeonatherapeutics.com

Answer: Abeona Therapeutics (Nasdaq: ABEO) is a fully-integrated gene and cell therapy company at the forefront of the rapidly-advancing field of genetic medicine. The Companys multi-platform expertise across the manufacture, delivery, development, and discovery of novel gene and cell therapies has it uniquely positioned for success. Underpinning the Companys robust pipeline is its fully-operational manufacturing facility producing therapies and vectors for preclinical and clinical studies. Abeona is also developing the AIMTM Vector Platform: 100+ next-generation AAV capsids for delivering gene therapies targeting a wide range of organs and multiple routes of delivery. A robust and diverse pipeline is led by a novel gene-corrected cell therapy poised to enter Phase 3 in mid-2019 and complemented by one-time gene therapy candidates across four lysosomal storage diseases. Several preclinical discoveries are led by an emerging program in cystic fibrosis that uses the AIM vector platform and a capsid that has shown potential across inherited and acquired retinal diseases.

Premium Sales Data for Prospecting

  • Sales data across over 200M records

  • Up-to-date records (less decayed data)

  • Accurate Email Lists (real-world tested)

  • Powerful search engine and intuitive interface

lock icon Get Full Access